Title |
Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data
|
---|---|
Published in |
ClinicoEconomics and Outcomes Research: CEOR, February 2017
|
DOI | 10.2147/ceor.s124381 |
Pubmed ID | |
Authors |
Valentin Brodszky, Anikó Bíró, Zoltán Szekanecz, Boglárka Soós, Petra Baji, Fanni Rencz, László Tóthfalusi, László Gulácsi, Márta Péntek |
Abstract |
To compare drug survival of biological therapies in patients with rheumatoid arthritis (RA), and analyze the determinants of discontinuation probabilities and switches to other biological therapies. Consecutive RA patients initiating first biological treatment in one rheumatology center between 2006 and 2013 were included. Log-rank test was used to analyze the differences between the survival curves of different biological drugs. Cox regression was applied to analyze the discontinuation due to inefficacy, the occurrence of adverse events, or to any reasons. A total of 540 patients were included in the analysis. The most frequently used first-line biological treatments were infliximab (N=176, 33%), adalimumab (N=150, 28%), and etanercept (N=132, 24%). Discontinuation of first tumor necrosis factor-alpha (TNF-α) treatment was observed for 347 (64%) patients, due to inefficacy (n=209, 60%), adverse events (n=103, 30%), and other reasons (n=35, 10%). Drug survival rates for TNF-α and non-TNF-α therapies were significantly different, and were in favor of non-TNF-α therapies. Every additional number of treatment significantly increased the risk of inefficacy by 27% (p<0.001) and of adverse events by 35% (p=0.002). After the discontinuation of the initial TNF-α treatment, switching to rituximab and tocilizumab was associated with significantly longer treatment duration than switching to a second TNF-α. The non-TNF-α therapies resulted in significantly longer treatment duration, due to both less adverse events and longer maintenance of effectiveness. Non-TNF-α therapies resulted in significantly longer treatment duration, and lost their effectiveness later. Increase in the number of switches significantly increased the risk of discontinuation of any biological therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 14% |
Other | 4 | 11% |
Student > Bachelor | 3 | 9% |
Student > Master | 3 | 9% |
Student > Postgraduate | 2 | 6% |
Other | 5 | 14% |
Unknown | 13 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 26% |
Medicine and Dentistry | 6 | 17% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Nursing and Health Professions | 1 | 3% |
Computer Science | 1 | 3% |
Other | 1 | 3% |
Unknown | 14 | 40% |